A polycaprolactone nanoparticle formulation of cyclosporin-a improves the prediction of area under the curve using a limited sampling strategy

International Journal of Pharmaceutics

Volumn 187, Issue 1, 1999, Pages 101-113

  Molpeceres, Jesus ^a   Chacón, Mercedes ^a   Guzmán, Manuel ^a   Berges, Laura ^a   Del Rosario Aberturas, María ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

AUC; Cyclosporine; Drug monitoring; Nanoparticles; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; NANOPARTICLE; POLYCAPROLACTONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MONITORING; FEMALE; MALE; MICROEMULSION; MODEL; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; RAT; REGRESSION ANALYSIS;

ANIMALS; AREA UNDER CURVE; CYCLOSPORINE; DRUG CARRIERS; DRUG MONITORING; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MALE; PARTICLE SIZE; POLYESTERS; PREDICTIVE VALUE OF TESTS; RATS; RATS, WISTAR;

EID: 0032850436     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00177-5     Document Type: Article

References (24)

1. Amante A.J., Kahan B.D. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate post transplant period. Transplant. Proc. 28:1996;2162-2163.
2. Amante A.J., Kahan B.D. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Clin. Chem. 42:1996;1294-1296.
3. Awni W.M., Heim-Duthoy K., Kasiske B.L. Monitoring of cyclosporine by serial posttransplant pharmacokinetic studies in renal transplant patients. Transplant. Proc. 22:1990;1343-1344.
4. Bennett W.M., DeMattos A., Norman D.J., Meyer M.M., Olyaei A. Which cyclosporin formulation? Lancet. 348:1996;205.
5. Cantarovich F., Bizollon C., Cantarovich D., Lefrancois N., Dubenard J.M., Traeger J. Cyclosporine plasma levels six hours after oral administration: a useful tool for monitoring therapy. Transplantation. 45:1988;389-394.
6. Cantarovich M., Latter D., Fitchett D. Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study. Transplant. Proc. 29:1997;602-604.
7. Friman S., Bäckman L. A new microemulsion formulation of cyclosporin. Pharmacokinetic and clinical features. Clin. Pharmacokinet. 30:1996;181-193.
8. Grevel J., Kahan B.D. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin. Chem. 37:1991;1905-1908.
9. Guzmán M., Molpeceres J., García F., Aberturas M.R., Rodríguez M. Formation and characterization of cyclosporine-loaded nanoparticles. J. Pharm. Sci. 82:1993;498-502.
10. Johnston A., Sketris I., Marsden J.T., Galustian C.G., Fashola T., Taube D., Pepper J., Holt D.W. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant. Proc. 22:1990;1345-1346.
11. Johnston A., Holt D.W. Which cyclosporin formulation? Lancet. 348:1996;1175.
12. Kahan B.D., Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation. 46:1988;631-644.
13. Lindholm A. Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther. Drug Monit. 17:1995;631-637.
14. Meyer M.M., Munar M., Udeaja J., Bennett W. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J. Am. Soc. Nephrol. 4:1993;1306-1315.
15. Molpeceres J., Guzmán M., Aberturas M.R., Chacón M., Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci. 85:1996;206-213.
16. Molpeceres, J., Chacón, M., Berges, L., Guzmán, M., Aberturas, M.R., 1998a. Dose-linearity of cyclosporine pharmacokinetics in rats: Polycaprolactone nanoparticles versus Sandimmun emulsion. In: Proc. 2nd World meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Paris, France.
17. Molpeceres, J., Chacón, M., Guzmán, M., Berges, L., Aberturas, M.R., 1998b. Increased oral bioavailability of cyclosporine incorporated in polycaprolactone nanoparticles. In: III Spanish-Portuguese Conference on Controlled Drug Delivery, Lisbon, Portugal.
18. Pollard S. Which cyclosporin formulation? Lancet. 348:1996;1175-1176.
19. Rial M.C., Frias S., Argento J., Tessler J., Casadei D. Convenience of level of cyclosporine-neoral at time 3 to determine the area under the curve in renal transplant. Transplant. Proc. 29:1997;292-293.
20. Rocha G., Deschênes J., Cantarovich M. Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis. Ophthalmology. 104:1997;245-251.
21. Sabbatiello R., Sgrosso J.L., Schiavelli R. et al. Cyclosporine Neoral monitoring and its correlation with the 'area under the curve'. Transplant. Proc. 28:1996;3378.
22. Serafinowicz A., Gaciong Z., Baçzkowska T., Rell K., Lao M., Walaszewski J. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmun-Neoral. Transplant. Proc. 28:1996;3138-3139.
23. Serafinowicz A., Gaciong Z., Majchrzak J. et al. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral. Transplant. Proc. 29:1997;277-279.
24. Serino F., Citterio F., Pozzetto U., Grevel J., Castagneto M. Abbreviated three-point kinetic profile in the 12-hour area under the curve for pharmacokinetic monitoring of cyclosporine. Transplant. Proc. 26:1994;2807-2808.